Loading…
Sanjivani Paranteral (BSE 531569)₹173.85−1.64%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Sanjivani Paranteral reported sales of ₹23.88 Cr, up 33.3% from Jun 2025, and net profit of ₹2.48 Cr, up 44.2% year on year. For the year to Mar 2026, sales were ₹68.75 Cr and net profit ₹6.68 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.00 | 12.88 | 16.47 | 18.17 | 17.37 | 18.22 | 17.91 | 15.54 | 22.11 | 13.23 | 23.88 |
| Expenses | 12.95 | 10.67 | 14.05 | 15.22 | 14.73 | 15.51 | 15.19 | 13.21 | 18.14 | 11.60 | 19.60 |
| Operating Profit | 1.96 | 2.15 | 2.33 | 2.84 | 2.54 | 2.60 | 2.63 | 2.24 | 3.83 | 1.56 | 4.16 |
| OPM % | 13.1% | 16.8% | 14.2% | 15.7% | 14.7% | 14.3% | 14.7% | 14.5% | 17.4% | 11.9% | 17.4% |
| Other Income | 0.24 | 0.04 | 0.08 | 0.38 | 0.30 | 0.42 | 0.03 | 0.15 | 0.29 | 0.59 | 0.14 |
| Interest | 0.09 | 0.10 | 0.03 | 0.19 | 0.18 | 0.21 | 0.23 | 0.04 | 0.20 | 0.30 | 0.34 |
| Depreciation | 0.23 | 0.25 | 0.12 | 0.16 | 0.17 | 0.17 | 0.17 | 0.16 | 0.22 | 0.67 | 0.64 |
| Profit before tax | 1.91 | 1.89 | 2.29 | 2.92 | 2.52 | 2.67 | 2.31 | 2.20 | 3.71 | 1.21 | 3.33 |
| Tax % | 13.2% | 33.5% | 24.5% | 21.3% | 24.3% | 17.3% | 24.8% | 25.1% | 24.9% | 55.0% | 25.0% |
| Net Profit | 1.64 | 1.25 | 1.70 | 2.29 | 1.89 | 2.18 | 1.72 | 1.63 | 2.77 | 0.54 | 2.48 |
| EPS (Rs) | 1.64 | 1.07 | 1.45 | 1.96 | 1.59 | 1.83 | 1.42 | 1.33 | 2.25 | 0.44 | 2.02 |
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales | 54.49 | 70.24 | 68.75 | 74.76 |
| Expenses | 46.04 | 59.52 | 58.19 | 62.55 |
| Operating Profit | 8.21 | 10.30 | 10.27 | 11.79 |
| OPM % | 15.1% | 14.7% | 15.0% | 15.8% |
| Other Income | 0.51 | 1.21 | 0.96 | 1.17 |
| Interest | 0.26 | 0.60 | 0.64 | 0.88 |
| Depreciation | 0.94 | 0.61 | 1.23 | 1.69 |
| Profit before tax | 7.59 | 10.36 | 9.41 | 10.45 |
| Tax % | 18.6% | 21.8% | 28.8% | — |
| Exceptional items | 0.00 | 0.00 | −0.10 | — |
| Net Profit | 6.15 | 8.08 | 6.68 | 7.42 |
| EPS (Rs) | 5.27 | 6.80 | 5.44 | 6.04 |
| Dividend payout % | 0.0% | 7.3% | 0.0% | — |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 11.63 | 11.85 | 12.24 |
| Reserves | 16.21 | 26.15 | 36.00 |
| Borrowings | 0.96 | 8.12 | 14.25 |
| Other Liabilities | 14.46 | 31.96 | 25.34 |
| Total Liabilities | 43.26 | 78.08 | 87.83 |
| Fixed Assets | 9.95 | 20.66 | 47.33 |
| CWIP | 0.00 | 19.13 | 1.16 |
| Investments | 0.00 | 0.00 | 0.72 |
| Other Assets | 33.31 | 38.29 | 38.62 |
| Inventories | 9.72 | 10.52 | 11.01 |
| Trade receivables | 4.71 | 16.69 | 15.46 |
| Cash & equivalents | 9.52 | 2.40 | 1.35 |
| Total Assets | 43.26 | 78.08 | 87.83 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −10.72 | 12.42 | −0.12 |
| Cash from investing activity | −12.20 | −21.89 | −9.98 |
| Cash from financing activity | 23.13 | 10.45 | 9.83 |
| Net cash flow | 0.23 | 0.93 | −0.23 |
| Capex | 3.29 | 30.30 | 10.17 |
| Free cash flow | −14.03 | −17.98 | −10.19 |
| CFO / OP % | −117.0% | 132.9% | 20.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 32 | 87 | 82 |
| Inventory days | 126 | 96 | 92 |
| Days payable | 73 | 137 | 30 |
| Cash conversion cycle | 83 | 44 | 143 |
| Working capital days | 36 | 0 | 46 |
| ROCE % | — | 28.5% | 18.0% |
For the Jun 2026 quarter, Sanjivani Paranteral reported sales of ₹23.88 Cr, up 33.3% year on year and net profit of ₹2.48 Cr, up 44.2% year on year. The operating margin was 17.4%.
Sanjivani Paranteral's sales for the year to Mar 2026 were ₹68.75 Cr; over the last twelve months they were ₹74.76 Cr.
Net profit for the year to Mar 2026 was ₹6.68 Cr, and ₹7.42 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.04.
Sanjivani Paranteral reported borrowings of ₹14.25 Cr at Mar 2026, against cash and equivalents of ₹1.35 Cr.
Cash from operations was −₹0.12 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹10.19 Cr.